Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone...

Area of Science:

• Ophthalmology
• Pharmacokinetics
• Biomedical Engineering

Background:

• Intravitreal therapies are crucial for treating various eye conditions.
• Fixed-dose regimens are common but may not account for individual anatomical variations.
• Vitreous cavity volume (VV) varies significantly with axial length (AL).

Purpose of the Study:

• To quantify the influence of anatomical variation in vitreous cavity volume on intravitreal drug concentration, therapeutic exposure duration, and intraocular pressure (IOP) dynamics.
• To model the pharmacokinetic behavior of fixed-dose intravitreal therapies across different eye sizes.

Main Methods:

• Theoretical pharmacokinetic modeling using the VIVEX equation to estimate VV based on AL.
• Application of a one-compartment first-order elimination model for triamcinolone acetonide and vancomycin.
• Monte Carlo simulations to assess population-level variability in pharmacokinetic outcomes.

Main Results:

• Modeled VV varied significantly, from 2.98 mL in small hyperopic eyes to 11.76 mL in large myopic eyes.
• Fixed intravitreal dosing resulted in approximately fourfold differences in initial drug concentration (C0) across eye sizes.
• Therapeutic exposure duration (t_eff) was reduced by ~50% for triamcinolone and by 2-3 days for vancomycin in larger eyes.
• Modeled acute IOP rise was substantially higher in small eyes (~4.3 mmHg) compared to large eyes (~1.1 mmHg).
• Anatomical variability accounted for ~30% of the modeled pharmacokinetic variance.

Conclusions:

• Substantial, predictable influence of anatomical differences in VV on intravitreal pharmacokinetics.
• Fixed intravitreal dosing leads to geometry-driven differences in drug exposure and IOP load.
• Biometry-stratified clinical studies are warranted to validate these findings and assess clinical relevance for intravitreal therapies.